Jeil Pharm and Jeil Pharma Holdings Hold Regular Shareholders' Meeting

Jeil Pharma Holdings, CEO Sangcheol Han Reappointed as Inside Director
Jeil Pharmaceutical, Notchikuk Reappointed as Inside Director and Head of Sales Division · Changseok Lee Newly Appointed as Head of Central Research Institute

Jeil Pharma Holdings Shareholders' Meeting.

[Asia Economy Reporter Lee Gwan-joo] Jeil Pharmaceutical announced on the 23rd that it held the 5th regular general shareholders' meeting at the auditorium of its headquarters in Seocho-gu, Seoul.

At the shareholders' meeting, Jeil Pharmaceutical reported key business performance, including achieving sales of 701.6 billion KRW last year. Along with this, Notchuk, Head of Sales Division, was reappointed as an inside director, and Lee Chang-seok, Head of the Central Research Institute, was newly appointed as an inside director. The agenda on the director remuneration limit was also approved as originally proposed.

Seong Seok-je, CEO of Jeil Pharmaceutical, said in his greeting, "Despite the difficult market environment, we have opened the era of 700 billion KRW in sales," adding, "This year as well, we will flexibly and proactively respond to rapidly changing environmental changes, overcoming them with selection and concentration, passion, and a spirit of challenge."

Jeil Pharma Holdings also held its 62nd regular general shareholders' meeting on the same day. The financial statements and consolidated financial statements, as well as the reappointment of CEO Han Sang-cheol as an inside director, were approved. The agenda on the director remuneration limit was also approved as originally proposed.

Han Sang-cheol, CEO of Jeil Pharma Holdings, emphasized, "The crisis in the healthcare sector caused by COVID-19 demands greater social responsibility from pharmaceutical companies," adding, "Although the uncertainty of the management environment is increasing, we will do our best to lead the stable growth of affiliates and further enhance corporate value through market-oriented thinking to innovate work processes, accurate judgment and decision-making, and swift execution."

Cash dividends were also approved at the shareholders' meeting. Jeil Pharma Holdings and Jeil Pharmaceutical decided to pay a dividend of 65 KRW per share each.

This content was produced with the assistance of AI translation services.